# Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

> **NCT01856257** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 71 (actual)

## Conditions studied

- Primary Renal Allograft Candidate
- Kidney Transplantation

## Interventions

- **BIOLOGICAL:** Anti-thymocyte Globulin (Rabbit)
- **BIOLOGICAL:** belatacept
- **DRUG:** methylprednisolone
- **BIOLOGICAL:** basiliximab
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT01856257
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Safety: Stopping rule not met.
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856257, "Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01856257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*